Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

There is a higher potential for downside than upside in Biogen Inc's (NASDAQ:BIIB) shares, UBS analysts said Thursday, lowering their price target on the stock from $234 to $202.

PGIM Jennison Health Sciences Fund released its second quarter 2024 investor letter. A copy of the letter can be downloaded ...

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...

Kisunla is a 0nce-a-month, 30-minute infusion that is shown to slow the progression of the disease by 37 percent and reduce Alzheimer's-causing plaques by 84 percent.

WASHINGTON, DC / ACCESSWIRE / October 1, 2024 / Boosting research investment into the health and wellbeing of adults with Down syndrome would ...

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs.

Karen Chung of Chester Springs has received one of the nation’s first treatments for early symptomatic Alzheimer’s disease, ...

The anticipation of competing data from GLP1 in 2025 and the expectation that Eli Lilly (NYSE:LLY)'s Kisunla will outpace Leqembi by year-end 2026 add to the headwinds facing Biogen. Neurologists ...